Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695198 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3361237 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03695198 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 64 participants.
The verdict
NCT03695198, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * The safety of LY3361237 and any side effects that might be associated with it. * How much LY3361237 gets into the blood stream and how long it takes the body to remove it in healthy participants. Participants will be admitted to the clinical research unit (CRU) for 4 overnight stays. The study will last about 12 weeks for each participant, not including screening.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG LY3361237 - SC
- DRUG LY3361237 - IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-10-26 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695198
The ClinicalTrials.gov registry entry for NCT03695198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo - IV is the first listed.
NCT03695198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695198 about?
NCT03695198 is a clinical study titled "A Study of LY3361237 in Healthy Participants". The purposes of this study are to determine: * The safety of LY3361237 and any side effects that might be associated with it. * How much LY3361237 gets into the blood stream and how long it takes the body to remove it in healthy participants. Participants will be admitted to the clinical research ...
What is the current status of trial NCT03695198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-10-26. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT03695198?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), LY3361237 - SC (DRUG), LY3361237 - IV (DRUG).
Who is sponsoring clinical trial NCT03695198?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.